Home Biosimilar Antibodies Metabolism PCSK9 antibody Bococizumab (Anti-PCSK9)
For research use only. Not for use in humans.

Bococizumab (Anti-PCSK9)

Synonyms: PF-04950615; RN316

Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.

Bococizumab (Anti-PCSK9)

Quality Control

Batch: Purity: 99% Protein concentration: 6.739mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation PCSK9
PF-06446846 0
PF-06446846 hydrochloride 0
SBC-110736 0
R-IMPP 0
SBC-115076 9
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD.
References

Product Details

CAS No. 1407495-02-6
Molecular Weight 145.06
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.